替考拉宁与万古霉素治疗革兰氏阳性菌感染的临床疗效和安全性对比的Meta分析

发布时间：2018-06-09 13:16

本文选题：替考拉宁 + 万古霉素　；参考：《中国临床药理学杂志》2017年02期

【摘要】：目的评价替考拉宁与万古霉素治疗革兰氏阳性菌感染的临床疗效与安全性。方法检索Pub Med、Em Base、The Cochrane Library、中国生物医学文献数据库、中国知网、维普和万方数据库中有关替考拉宁与万古霉素治疗革兰氏阳性菌感染的随机对照试验(RCT),截至2015年11月。用Rev Man 5.3软件进行分类整理,对治疗革兰氏阳性菌感染的有效率、细菌清除率和药物不良反应发生率、肾毒性发生率和全因死亡率进行分析。结果共纳入45个RCT,共3645例革兰氏阳性菌感染的患者。Meta分析结果显示,替考拉宁组与万古霉素组的有效率分别为79.19%和78.71%,细菌清除率分别为86.81%和85.39%,全因死亡率分别为10.47%和10.60%,差异均无统计学意义(P0.05);但替考拉宁组与万古霉素组的全部药物不良反应发生率9.28%和16.70%,肾毒性发生率分别为3.15%和8.54%,差异均有统计学意义(P0.01)。结论替考拉宁治疗革兰氏阳性菌感染的临床疗效与万古霉素相似,但药物不良反应的发生率、肾毒性的发生率均低于万古霉素,安全性更好。
[Abstract]:Objective to evaluate the efficacy and safety of teicoplanin and vancomycin in the treatment of Gram-positive bacteria infection. Methods A randomized controlled trial of teicoplanin and vancomycin for the treatment of Gram-positive bacilli infection was conducted in Pub Meden Em Base of the Cochrane Library, Chinese Biomedical Literature Database, China knowledge Network, Weip and Wanfang databases, up to November 2015. The effective rate, bacterial clearance rate, adverse drug reaction rate, nephrotoxicity rate and all-cause mortality of Gram-positive bacteria infection were analyzed by using the software Rev Man 5.3. Results A total of 45 RCTs were included, and 3645 patients with Gram-positive bacilli infection. The effective rates of teicoplanin group and vancomycin group were 79.19% and 78.71%, the bacterial clearance rates were 86.81% and 85.39%, and the total mortality rate were 10.47% and 10.60%, respectively. The incidence of adverse reactions was 9.28% and 16.70%, and the incidence of nephrotoxicity was 3.15% and 8.54, respectively. The difference was statistically significant (P 0.01). Conclusion the clinical efficacy of teicoplanin in the treatment of Gram-positive bacilli infection is similar to that of vancomycin, but the incidence of adverse drug reactions and nephrotoxicity is lower than that of vancomycin, and the safety of teicoplanin is better than that of vancomycin.
【作者单位】：中国人民解放军总医院药物/器械临床试验中心;中国人民解放军总医院呼吸科;大理大学药学与化学学院;武汉大学循证与转化医学中心;
【分类号】：R51

【相似文献】